Mujer de Queensland con mieloma recaído viaja a Shanghái para CAR-T de doble blanco

When
2025
City
Shanghai
Costo total informado
Not reported
Shared on
Patient organisation story
Patient from
Australia
AutoinformadoVerificado

Cronologia

2018
Diagnosed with aggressive myeloma; tandem and later a third stem cell transplant.
2025
Relapses; not eligible for Australian CAR-T trials. Contacts a New Zealand patient found on Facebook, then emails a Shanghai professor who replies the same day.
2025
Three weeks later flies to China; T cells sent to Beijing for manufacturing; BCMA and GPRC5D CAR-T infused.
2025
Two weeks in hospital after infusion, mild CRS, readmitted for a viral respiratory infection; seven weeks in China total.

Lo que fue bien

Lo que fue dificil

Individual experience; outcomes vary. This story is a summary linking to its source; follow the link for the original account.

Fuente

  1. Travelling to China for CAR T-cell therapy (Amanda's story)
    Myeloma Australia · self-reported · accessed 2026-10-26

Solo informacion. No es consejo medico, diagnostico ni recomendacion de tratamiento. Consulte a su medico. En una emergencia, llame a su numero local de emergencias.